MED12 and non-small cell lung carcinoma: To verify whether this effect was due to the reduced expression of MED12, we restored wild-type MED12 expression in MED12 KO NSCLC cell lines and confirmed the recovery of sensitivity to RTK inhibitors (Fig. 1E, F and Supplementary Fig. S4).